Faron Pharmaceuticals reports new data for cancer drug Clevegen

Faron Pharmaceuticals has reported new findings from the open-label Phase I/II MATINS clinical trial of its cancer immunotherapy Clevegen for the treatment of certain metastatic or inoperable solid tumours.